Mosaic ImmunoEngineering Reports Increased Net Loss and Dwindling Cash Reserves

Mosaic ImmunoEngineering, Inc. reported a net loss of $177,496 for the three months ended June 30, 2026, compared to a loss of $172,028 for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $352,847, slightly down from $353,348 in the prior year. The company's total operating expenses for the second quarter of 2026 were $156,721, an increase from $148,854 in the same quarter of 2025. The increase in expenses was primarily attributed to higher general and administrative costs, which rose to $141,113 from $132,848 year-over-year.

Mosaic's financial position has seen significant changes, particularly in its cash reserves, which dwindled to $26 as of June 30, 2026, down from $3.6 million at the end of 2025. The company's total liabilities increased to $7.8 million from $7.5 million, driven by higher accounts payable and accrued compensation. The accumulated deficit also widened to $9.9 million from $9.5 million, reflecting ongoing operational losses. The company has not generated any revenue to date, and its ability to continue operations is heavily reliant on raising additional capital.

Strategically, Mosaic is focused on advancing its immunotherapy pipeline, particularly through a binding term sheet with Oncotelic Therapeutics, which aims to acquire rights to certain cancer therapies and AI technologies. This agreement, valued at $15 million, is contingent upon various conditions, including shareholder approval and waivers from convertible noteholders. The company is also actively seeking to secure financing through potential equity offerings and partnerships to support its operations and development programs.

Operationally, Mosaic has maintained a consistent employee headcount, with no significant changes reported. The company continues to engage in research and development activities, although its limited cash position has constrained its ability to expand its product pipeline. The management has indicated that it is exploring various financing options to address its liquidity challenges, but uncertainties remain regarding the availability of capital on favorable terms. The company has expressed concerns about its ability to continue as a going concern if it cannot secure additional funding.

Looking ahead, Mosaic ImmunoEngineering acknowledges the challenges it faces in raising capital and the potential impact of broader economic conditions on its operations. The company is committed to pursuing strategic partnerships and financing opportunities to support its ongoing research and development efforts, but it has cautioned that there can be no assurance of success in these endeavors. The management's outlook remains cautious, emphasizing the need for immediate capital to sustain operations and advance its immunotherapy initiatives.